9939 — Kintor Pharmaceutical Share News
0.000.00%
Last trade - 00:00- HK$750.48m
- HK$870.57m
- CNY32.68m
Brief: Kintor Pharmaceutical Posts FY Loss And Total Comprehensive Loss RMB954.4 Mln
Brief: Kintor Pharma Announces Positive Early Stage Study Results Of Topical Use Compound
Brief: Kintor Pharmaceutical Is Considering Proposed Top-Up Placing And Share Placement Arrangement
Brief: Kintor Pharma's Female Androgenetic Alopecia Drug met Main Goal Of Phase Ii Study In China
Brief: Legend's Long Position In Ordinary Shares Of Kintor Pharmaceutical Falls To 4.99% - HKEX Filing
Brief: Kintor Pharma Announces Completion Of Subject Enrollment And Dosing In Phase I Clinical Trial Of AR-PROTAC(Gt20029) In The US
Brief: Kintor Pharmaceutical Says Application Made For Resumption Of Trading From 9:00AM On Sept 1
Brief: Kintor Pharmaceutical Says Trading In Shares Of Co On Stock Exchange Of HK Halted On 31 Aug
Brief: Kintor Pharmaceutical Says KT International Investment Agreed To Sell 34.1 Million Shares In Aggregate
Brief: Kintor Pharmaceutical Proposes Top-Up Placing With Placing Price Expected To Be HK$13.8/Share
China's Kintor Pharma falls most in 11 weeks on wider H1 loss
Brief: Kintor Pharmaceutical Posts HY Adjusted Loss RMB468.6 Million
Brief: Kintor Pharma Announces Completion Of Patient Enrollment In Phase II Clinical Trial Of Kx-826 For Treatment Of Androgenetic Alopecia In U.S.
China approves Genuine Biotech's HIV drug for COVID patients (updated)
Brief: Kintor Pharmaceutical CFO's Long Position In H-Share Of The Company Falls To 0.59% - Filing
Brief: Kintor Pharma Announces Inclusion In MSCI China Index
Brief: Kintor Pharma Announces First Patient Dosing In Multi-Regional Global Phase Ii Clinical Trial Of Alk-1 Antibody And Nivolumab Combination Therapy For The Treatment Of Advanced Hepatocellular Carcinoma
China Kintor's COVID drug candidate cuts hospital, death risk in trial
Brief: Kintor Pharmaceutical Announces Top-Line Data Of Phase III Study Of COVID-19 Drug